← Patent-cliff monitor Biotechnology company
Company LinkedIn URL https://www.linkedin.com/authwall?trk=gf&trkInfo=AQHC4bZjeFcZ7wAAAYB1XGiATjStc7oyIixcVtRC42ORLbQ_lgG891EtpZyP6mHKSp_39G_5T_-rAOZ6qgjazLftFZRLuRmxfe5s7cFt-T6CxXbcqsCuTOF--ZLsMcxbtja3y30=&originalReferer=https://www.janssen.com/&sessionRedirect=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fjanssen-pharmaceutical-companies-of-johnson-and-johnson Twitter URL https://twitter.com/JanssenUS Official Website http://www.janssenbiotech.com/ Wikidata ID Q1053653 YouTube Channel https://www.youtube.com/channel/UC_MQ6DEfo6KBy6qsxWl645w
33 upcoming patent cliffs Drug Ingredient Type Cliff
Remicade infliximab Biologic Aug 2010 Simponi golimumab Biologic Apr 2021 Simponi golimumab Biologic Apr 2021 Stelara ustekinumab Biologic Sep 2021 Stelara ustekinumab Biologic Dec 2021 Stelara ustekinumab Biologic Dec 2021 Simponi golimumab Biologic May 2025 Simponi golimumab Biologic May 2025 Simponi Aria golimumab Biologic Jul 2025 Darzalex daratumumab Biologic Nov 2027 Darzalex daratumumab Biologic Nov 2027 Stelara ustekinumab Biologic Sep 2028 Tremfya guselkumab Biologic Jul 2029 Tremfya guselkumab Biologic Jan 2031 Darzalex Faspro daratumumab and hyaluronidase-fihj Biologic May 2032 Rybrevant amivantamab-vmjw Biologic May 2033 Carvykti ciltacabtagene autoleucel Biologic Feb 2034 INLEXZO GEMCITABINE HYDROCHLORIDE Small mol. Aug 2034 Tecvayli teclistamab-cqyv Biologic Oct 2034 Tecvayli teclistamab-cqyv Biologic Oct 2034 Talvey talquetamab-tgvs Biologic Aug 2035 Talvey talquetamab-tgvs Biologic Aug 2035 Tremfya guselkumab Biologic Sep 2036 Tremfya guselkumab Biologic Sep 2036 Tremfya guselkumab Biologic Sep 2036 Tremfya guselkumab Biologic Mar 2037 Imaavy nipocalimab-aahu Biologic Apr 2037 Imaavy nipocalimab-aahu Biologic Apr 2037 BALVERSA ERDAFITINIB Small mol. Feb 2038 BALVERSA ERDAFITINIB Small mol. Feb 2038 BALVERSA ERDAFITINIB Small mol. Feb 2038 Rybrevant Faspro amivantamab and hyaluronidase-lpuj Biologic Feb 2038 Rybrevant Faspro amivantamab and hyaluronidase-lpuj Biologic Feb 2038 Rybrevant Faspro amivantamab and hyaluronidase-lpuj Biologic Feb 2038 Rybrevant Faspro amivantamab and hyaluronidase-lpuj Biologic Feb 2038 AKEEGA ABIRATERONE ACETATE; NIRAPARIB TOSYLATE Small mol. Mar 2038 AKEEGA ABIRATERONE ACETATE; NIRAPARIB TOSYLATE Small mol. Mar 2038 ERLEADA APALUTAMIDE Small mol. Jan 2041 ERLEADA APALUTAMIDE Small mol. Jan 2041 LAZCLUZE LAZERTINIB MESYLATE Small mol. Aug 2041 LAZCLUZE LAZERTINIB MESYLATE Small mol. Aug 2041 ICOTYDE ICOTROKINRA HYDROCHLORIDE Small mol. Nov 2041 ZYTIGA ABIRATERONE ACETATE Small mol. — ZYTIGA ABIRATERONE ACETATE Small mol. — Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.